Developing a cream to relieve pain from burns by blocking specific pain receptors.
Official title: Topical treatment for burn pain by blocking cutaneous pain receptors.
Funded at Serentrix, LLC · NIH-10821060 · Data updated 2026-11-12
This study is testing a new cream that could help relieve burn pain by targeting specific pain receptors in the skin, and it's designed for anyone suffering from burns who wants a treatment with fewer side effects than traditional pain medications.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Serentrix, LLC NIH-funded |
| Lab location | 1 site (Exton, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $340,685 |
| NIH project number | 1R43GM150295-01A1 |
| Project ID | NIH-10821060 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from burn injuries who experience significant pain.
✕Less likely to help
Patients with burn injuries who do not experience pain or those with other underlying conditions that complicate pain management may not benefit from this research.
What this research studies
This research aims to create a topical treatment for burn pain by targeting the TRPV1 pain receptors in the skin. The approach involves applying a small molecule antagonist directly to the affected area, which has shown promise in animal models for reducing pain and inflammation. By focusing on a localized treatment, the researchers hope to minimize side effects associated with systemic pain medications. The lead compound, SER114, has already been tested in early clinical trials for other types of pain, indicating its potential effectiveness.
Why it matters
Potential benefit: If successful, this research could provide a new, effective way to manage pain for burn victims, improving their recovery experience.
How similar studies have gone: Previous research has shown success with similar approaches targeting TRPV1 receptors for pain management, indicating a promising avenue for this treatment.
Where this research is happening
-
Serentrix, LLC
Exton, United States Active
Researchers
- Principal investigator: Bhargava, Kumaril — Serentrix, LLC
- Study coordinator: Bhargava, Kumaril
Related research
Other NIH-funded projects on the same topics.
-
A non-opioid topical cream that eases burn pain by blocking skin pain receptors
This project is creating a non-opioid skin cream that targets TRPV1 pain receptors to help people with burn-related pain feel less pain.
-
Testing a new drug to relieve pain from endometriosis
This study is testing a new drug called SER-014 to see if it can help relieve pain from endometriosis without the risks of addiction, offering a safer option for women who struggle with this condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.